These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 17848273)

  • 1. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
    Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
    Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
    Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
    Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
    Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
    J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas.
    Lee TL; Yeh J; Friedman J; Yan B; Yang X; Yeh NT; Van Waes C; Chen Z
    Int J Cancer; 2008 May; 122(9):1987-98. PubMed ID: 18172861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
    Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
    Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in the p53 pathway and their association with radio- and chemosensitivity in head and neck squamous cell carcinoma.
    Hoffmann TK; Sonkoly E; Hauser U; van Lierop A; Whiteside TL; Klussmann JP; Hafner D; Schuler P; Friebe-Hoffmann U; Scheckenbach K; Erjala K; Grénman R; Schipper J; Bier H; Balz V
    Oral Oncol; 2008 Dec; 44(12):1100-9. PubMed ID: 18487078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
    Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
    Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
    Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
    Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bcl-xL inhibits p53- but not apoptin-induced apoptosis in head and neck squamous cell carcinoma cell line.
    Schoop RA; Kooistra K; Baatenburg De Jong RJ; Noteborn MH
    Int J Cancer; 2004 Mar; 109(1):38-42. PubMed ID: 14735465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
    Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
    Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer.
    Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M
    FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel associated pathways in cisplatin resistant head and neck squamous cell carcinoma: a pilot study.
    Yoo GH; Lin HS; Iskander AJ; Piechocki MP; Oliver J; Kewson D; Lonardo F; Tainsky MA; Kim HR; Kim H; Ensley JF
    Laryngoscope; 2005 Nov; 115(11):1938-46. PubMed ID: 16319602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of excision repair cross-complementation group 1 by Snail contributes to cisplatin resistance in head and neck cancer.
    Hsu DS; Lan HY; Huang CH; Tai SK; Chang SY; Tsai TL; Chang CC; Tzeng CH; Wu KJ; Kao JY; Yang MH
    Clin Cancer Res; 2010 Sep; 16(18):4561-71. PubMed ID: 20823140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines.
    Lee SK; Kim SB; Kim JS; Moon CH; Han MS; Lee BJ; Chung DK; Min YJ; Park JH; Choi DH; Cho HR; Park SK; Park JW
    Int J Cancer; 2005 Oct; 117(1):32-40. PubMed ID: 15880358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
    Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
    J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bcl-xL expression and regulation in the progression, recurrence, and cisplatin resistance of oral cancer.
    Alam M; Mishra R
    Life Sci; 2021 Sep; 280():119705. PubMed ID: 34111459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
    Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
    Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced cisplatin sensitivity of head and neck squamous cell carcinoma cell lines correlates with mutations affecting the COOH-terminal nuclear localization signal of p53.
    Mandic R; Schamberger CJ; Müller JF; Geyer M; Zhu L; Carey TE; Grénman R; Dünne AA; Werner JA
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6845-52. PubMed ID: 16203773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 and bcl-2 expression in locally advanced squamous cell head-neck cancer treated with platinum based chemotherapy and radiotherapy.
    Giatromanolaki A; Koukourakis M; Zaramboukas T; Skordalaki A; Arapantoni P; Georgoulias V; Fountzilas G
    Anticancer Res; 1998; 18(6B):4685-92. PubMed ID: 9891541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.